ANI Pharmaceuticals ANIP Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's total liabilities?
- ANI Pharmaceuticals (ANIP) reported total liabilities of $859.67M in Q1 2026.
- How has ANI Pharmaceuticals's total liabilities changed year-over-year?
- ANI Pharmaceuticals's total liabilities increased by 1.3% year-over-year, from $848.96M to $859.67M.
- What is the long-term trend for ANI Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's total liabilities has grown at a 27.6% compound annual growth rate (CAGR), from $265.49M to $899.65M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.